GLP-1 Receptor Agonists Beyond Weight Loss: Reading SELECT and FLOW

The organ protection seen with semaglutide is not simply a reward for losing weight. In the SELECT trial it lowered major cardiovascular events by roughly 20 percent in people with obesity and heart disease but no diabetes, and in the FLOW trial it lowered major kidney events by about 24 percent in adults with type 2 diabetes and chronic kidney disease. In both, the size of the benefit is larger than weight loss on its own can account for, which is the whole reason you should read these two trials line by line rather than by headline.

Key points#

• SELECT (NEJM, 2023) tested semaglutide in people with obesity and known heart disease but deliberately without diabetes, and cut major cardiovascular events by about 20 percent.
• FLOW (NEJM, 2024) tested a lower dose in type 2 diabetes with kidney disease and cut major kidney events by about 24 percent, so clearly that the trial was stopped early.
• The benefit curves separated early, and the effects appeared even where weight loss was modest, both pointing past weight as the sole driver.
• Each result applies to the population that was actually enrolled, not to everyone who might take the drug.

The question the two trials were built to settle#

GLP-1 receptor agonists were designed to lower blood sugar. Weight loss followed, and for several years that was where the account ended. The sharper scientific question is what accounts for the heart and kidney protection that later appeared: is it the downstream payoff of a smaller waistline and better glucose, or does the molecule act more directly on blood vessels, cardiac tissue, and the filtering units of the kidney?

The distinction is not academic. If the entire benefit rode on weight, then any method that took off the same number of pounds should deliver the same protection, and the choice of drug would matter far less. A marketing brochure cannot resolve this. Counting hard events over years can. That is what SELECT and FLOW set out to count: heart attacks, strokes, kidney failure, and death.

SELECT: heart protection with diabetes taken off the table#

SELECT enrolled adults who were overweight or obese and already had established cardiovascular disease, while screening out anyone with diabetes. Removing diabetes was the clever part of the design. These participants began with near-normal blood sugar and had almost no room to improve it, so glucose lowering could not sit in as a hidden explanation for whatever the trial found. It works something like a natural experiment: hold glucose roughly constant, and watch what happens to the heart.

Across a mean follow-up of more than three years, once-weekly semaglutide 2.4 mg reduced the primary composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by roughly 20 percent versus placebo, a hazard ratio close to 0.80. The absolute gap was smaller, on the order of 1.5 percentage points. That pairing is worth holding onto, whichever number is quoted: a striking relative figure can sit on top of a fairly low baseline event rate, and both are true at once.

The mechanistic hint lives in the timing. The event curves began to pull apart early, before most of the weight loss had accumulated. Prespecified analyses reinforced the point. How much weight a person shed early on did not neatly predict who avoided cardiovascular events, and mediation modeling attributed only about a third of the benefit to reductions in waist size. In plain terms, most of the cardiovascular protection was not explained by the scale. A review in the American Journal of Kidney Diseases appraising both trials read the pattern as evidence for direct vascular and anti-inflammatory action rather than weight alone. What SELECT could not do is name a single pathway. It shows the benefit is largely weight-independent, not exactly why.

FLOW: slowing the slide in kidney function#

FLOW posed the parallel question for the kidney. It randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo, with a median follow-up of about 3.4 years. The primary endpoint bundled the outcomes that matter most to a nephrologist: onset of kidney failure, a sustained fall of 50 percent or more in eGFR, or death from kidney or cardiovascular causes.

Semaglutide reduced that composite by about 24 percent, a hazard ratio near 0.76, and the trial was halted early once the benefit was unmistakable. Two secondary findings add detail. The annual rate of kidney function decline, the eGFR slope, was meaningfully gentler with semaglutide, by roughly 1.2 mL/min/1.73 m2 per year, which over time is the difference between holding steady and drifting toward dialysis. Cardiovascular events fell by about 18 percent, and all-cause death dropped as well. A prespecified analysis found the kidney benefit held whether or not participants were also on an SGLT2 inhibitor, suggesting semaglutide layers protection on top of that already kidney-protective class rather than simply doing the same job twice.

The weight-loss account comes up short here too. FLOW used the 1.0 mg diabetes dose, which produces far less weight loss than the 2.4 mg dose studied in obesity, yet the kidney signal was substantial. A benefit that stays strong while weight loss shrinks is hard to pin on weight. It fits better with direct effects on kidney inflammation, on the pressure inside the glomerulus, and on albuminuria.

Reading the weight-loss signal honestly#

Put the two trials side by side and they lean the same way. SELECT offers early curve separation and mediation work that credits weight for only part of the effect. FLOW offers a strong result at a dose that moves the scale much less. Together they support a reading in which weight loss contributes but does not carry the majority of the organ protection.

What neither trial delivers is a tidy mechanistic ledger that assigns each percentage point of benefit to a named cause. And the populations set firm edges on the conclusions. SELECT studied people with prior cardiovascular disease and obesity but no diabetes. FLOW studied type 2 diabetes with existing kidney disease. Stretching those numbers to healthier people, or to groups the trials never enrolled, is an assumption rather than a finding. Check which of the two populations you or your patient actually resembles before carrying a number across. Reading what a study randomized, and refusing to over-read it, is the core discipline of clinical evidence appraisal, and it is what keeps "beyond weight loss" an honest claim instead of a slogan.

Bottom line#

SELECT and FLOW moved GLP-1 receptor agonists from glucose-and-weight medicines to agents with proven hard-outcome benefits for the heart and kidney, in specific and well-defined populations. The evidence favors direct organ effects added to, not substituted for, the gains from weight and glucose. The honest caveats are the population limits, the modest absolute risk reductions sitting beneath the large relative ones, and the fact that "beyond weight loss" names a direction the data support rather than a fully charted map.